PaxMedica, Inc. Common Stock (PXMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PaxMedica, Inc. Common Stock (PXMD) trades at $0.0008 with AI Score 48/100 (Grade C). PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing anti-purinergic drug therapies for complex neurological disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for PXMD: PXMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PXMD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PXMD: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
PaxMedica, Inc. Common Stock (PXMD) Healthcare & Pipeline Overview
PaxMedica, Inc. specializes in clinical-stage biopharmaceuticals, developing anti-purinergic drug therapies to treat complex neurological disorders, including autism spectrum disorder and long COVID, positioning itself as a key player in addressing significant unmet medical needs.
What Is the Investment Thesis for PXMD?
PaxMedica, Inc. is poised for growth driven by its innovative drug pipeline, particularly with PAX-101 and PAX-102 targeting high-need areas such as autism spectrum disorder and long COVID. With ongoing clinical trials and potential partnerships for development and commercialization, PaxMedica's strategic focus on anti-purinergic therapies could yield substantial returns. However, the company faces challenges typical of clinical-stage biopharmaceuticals, including regulatory hurdles and the need for successful trial outcomes. As of now, PaxMedica's market cap is $0.00B, reflecting its early-stage status, but successful advancements in its drug pipeline could dramatically enhance its valuation in the coming years.
Based on FMP financials and quantitative analysis
PXMD Key Highlights
Market Cap: $0.00B, indicating the company's early-stage development status.
- Beta: -0.56, suggesting lower volatility compared to the market.
- No dividend yield, as the company is reinvesting in clinical development.
- Small workforce of 6 employees, indicating a lean operational model.
- Focus on addressing unmet medical needs in neurological disorders.
Who Are PXMD's Competitors?
PXMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| SRPT Sarepta Therapeutics | $19.22 | -2.58% | $2.03B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PXMD's Key Strengths?
Innovative drug pipeline targeting high-need neurological conditions.
- Strong focus on clinical development and research.
- Agile organizational structure with a small, dedicated team.
What Are PXMD's Weaknesses?
Limited financial resources typical of early-stage biopharmaceutical companies.
- Dependence on successful clinical trial outcomes for future growth.
- Small workforce may limit operational capacity.
What Could Drive PXMD Stock Higher?
Results from ongoing clinical trials for PAX-101 expected in Q4 2026.
- Development of PAX-102, with potential for intranasal administration benefits.
- Strategic partnership discussions to enhance drug development capabilities.
- Regulatory engagement to facilitate the approval process for PAX-101.
What Are the Key Risks for PXMD?
Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could delay drug approval timelines.
- Dependence on successful clinical trial outcomes for future growth.
- Competition from established biopharmaceutical companies with more resources.
- Market volatility affecting funding and investor sentiment.
What Are the Growth Opportunities for PXMD?
- PaxMedica's PAX-101, targeting autism spectrum disorder, positions the company to capture a significant share of this growing market. The increasing prevalence of autism diagnoses and the need for effective treatments create a favorable environment for PaxMedica's innovative therapies.
- Growth opportunity 2: The chronic fatigue syndrome market is gaining attention, with growing recognition of the condition's impact on quality of life. As awareness increases, the demand for effective treatments is expected to rise. PaxMedica's focus on PAX-101 for myalgic encephalomyelitis/chronic fatigue syndrome could lead to substantial market penetration, particularly as clinical results demonstrate efficacy.
- Growth opportunity 3: Post-COVID-19 syndrome, or long COVID, represents a new frontier in healthcare, with millions of individuals experiencing lingering symptoms. PaxMedica's PAX-101 is being explored for this indication, potentially tapping into a market that could see exponential growth as more patients seek solutions for their ongoing health challenges.
- Growth opportunity 4: The development of PAX-102, an intranasal formulation of suramin, opens new avenues for treatment delivery and patient compliance. This innovative approach could enhance the therapeutic landscape for neurological conditions, providing PaxMedica with a competitive edge in a market that values convenience and efficacy.
- Growth opportunity 5: Strategic partnerships with larger pharmaceutical companies could facilitate accelerated development and commercialization of PaxMedica's drug candidates. Collaborations may provide access to additional resources, expertise, and distribution channels, significantly enhancing the company's growth trajectory and market reach.
What Are PXMD's Competitive Advantages?
- Innovative focus on anti-purinergic therapies, addressing complex neurological disorders.
- Strong potential market demand for effective treatments in underserved areas.
- Small team allows for agile decision-making and rapid response to market changes.
What Does PXMD Do?
PaxMedica, Inc., incorporated in 2018 and headquartered in Tarrytown, New York, is a biopharmaceutical company dedicated to advancing anti-purinergic drug therapies (APTs). Originally founded as Purinix Pharmaceuticals LLC, the company rebranded to its current name in April 2020 to reflect its focus on innovative treatments for complex neurological disorders characterized by stubborn and persistent symptoms. The company is currently in the clinical development phase, with its lead investigational drug, PAX-101, an intravenous formulation of suramin, being explored for a variety of conditions, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly referred to as long COVID), and human African trypanosomiasis. Additionally, PaxMedica is developing PAX-102, an intranasal version of suramin, aimed at various neurological applications. With a small team of six employees, PaxMedica operates as a subsidiary of Tardimed Sciences LLC, leveraging its parent company's resources and expertise to drive its clinical programs forward. The company is committed to addressing significant gaps in treatment options for patients suffering from debilitating neurological conditions, positioning itself as an innovative player in the biotechnology sector.
What Products and Services Does PXMD Offer?
- Develop anti-purinergic drug therapies for neurological disorders.
- Focus on complex conditions with persistent symptoms.
- Lead product candidate is PAX-101, an intravenous formulation of suramin.
- Exploring treatments for autism spectrum disorder, chronic fatigue syndrome, and long COVID.
- Developing PAX-102, an intranasal version of suramin.
- Operate as a subsidiary of Tardimed Sciences LLC.
How Does PXMD Make Money?
- Generate revenue through the development and potential commercialization of innovative therapies.
- Focus on clinical trials to validate the efficacy of drug candidates.
- Potential partnerships with larger pharmaceutical companies for co-development and distribution.
- Aim to address significant unmet medical needs in the healthcare market.
What Industry Does PXMD Operate In?
The biotechnology industry is experiencing robust growth, driven by increasing demand for innovative therapies and advancements in genetic and cellular research. The market for neurological disorder treatments is expanding, with a growing emphasis on personalized medicine and targeted therapies. PaxMedica, Inc. is positioned within this landscape as it develops anti-purinergic drug therapies, which have the potential to address significant gaps in treatment options for conditions like autism and chronic fatigue syndrome. As the industry continues to evolve, companies like PaxMedica that focus on complex neurological disorders may find increasing opportunities for growth and collaboration.
Who Are PXMD's Key Customers?
- Patients suffering from neurological disorders.
- Healthcare providers seeking effective treatment options.
- Pharmaceutical partners interested in collaboration for drug development.
Financial Health
PaxMedica, Inc. Common Stock's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PaxMedica, Inc. Common Stock (PXMD) Valuation Context
Relative to its peer group, PXMD's quantitative score of 48/100 is below the peer average of 86/100.
Company Profile
PaxMedica, Inc. Common Stock operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tarrytown, US. The company is led by CEO Howard J. Weisman. PXMD has traded publicly since 2022.
Earnings Track Record
PaxMedica, Inc. Common Stock has missed Wall Street's EPS estimate in 4 of its last 4 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 35.3% below estimates on average.
PXMD Financials
Bull Case vs Bear Case
Bull Case
- Innovative drug pipeline targeting high-need neurological conditions.
- Strong focus on clinical development and research.
- Agile organizational structure with a small, dedicated team.
- Upcoming: Results from ongoing clinical trials for PAX-101 expected in Q4 2026.
Bear Case
- Limited financial resources typical of early-stage biopharmaceutical companies.
- Dependence on successful clinical trial outcomes for future growth.
- Small workforce may limit operational capacity.
- Potential: Regulatory hurdles that could delay drug approval timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PXMD Latest News
No recent news available for PXMD.
PXMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PXMD.
Price Targets
Wall Street price target analysis for PXMD.
PXMD MoonshotScore
What does this score mean?
The MoonshotScore rates PXMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Howard J. Weisman
CEO
Howard J. Weisman has a distinguished career in the biopharmaceutical industry, with extensive experience in drug development and commercialization. He has held various leadership roles, focusing on advancing innovative therapies and navigating complex regulatory environments. Weisman holds a degree in a relevant field and has been instrumental in guiding PaxMedica's strategic direction since its inception.
Track Record: Under Howard Weisman’s leadership, PaxMedica has made significant strides in developing its drug pipeline, particularly with PAX-101 and PAX-102. His strategic vision has positioned the company to explore critical partnerships and funding opportunities, enhancing its growth potential.
PXMD OTC Market Information
The OTC Other tier represents stocks that are not listed on major exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements, which can lead to lower visibility and liquidity compared to their listed counterparts. This tier often includes smaller or emerging companies, like PaxMedica, that are in early stages of development.
- OTC Tier: OTC Other
- Limited financial disclosures can increase investment risk.
- Lower trading volumes may lead to higher volatility.
- Regulatory uncertainties can impact the company's drug development timelines.
- Verify the company's clinical trial progress and results.
- Assess the management team's experience and track record.
- Review any partnerships or collaborations in place.
- Examine market demand for the company's drug candidates.
- Investigate potential regulatory hurdles that may arise.
- Incorporation as a biopharmaceutical company focused on innovative therapies.
- Rebranding to PaxMedica, Inc. reflects a clear strategic focus.
- Affiliation with Tardimed Sciences LLC provides additional credibility.
PaxMedica, Inc. Common Stock Healthcare Stock: Key Questions Answered
What does the AI Score mean for PXMD?
PXMD holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing anti-purinergic drug therapies for complex neurological disorders. The company aims to address unmet medical …
What does PaxMedica, Inc. Common Stock do?
PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurological disorders. Its lead product candidate, PAX-101, is an intravenous formulation of suramin aimed at treating conditions such as autism spectrum disorder, chronic fatigue syndrome, and long COVID.
What are the main risks for PXMD?
PaxMedica, Inc. faces several risks, including regulatory hurdles that could impact drug approval timelines, dependence on successful clinical trial outcomes, and competition from larger biopharmaceutical companies. Additionally, market volatility may affect funding opportunities, posing challenges for its growth strategy.
What is PaxMedica, Inc. Common Stock's drug pipeline status?
PaxMedica, Inc. is currently advancing its drug pipeline, with PAX-101 in clinical trials for various indications, including autism spectrum disorder and long COVID. The company is also developing PAX-102, an intranasal formulation of suramin, which is intended for neurological applications, positioning the company for potential future growth.
What are the key factors to evaluate for PXMD?
PaxMedica, Inc. Common Stock (PXMD) holds an AI score of 48/100 (low). is poised for growth driven by its innovative drug pipeline, particularly with PAX-101 and PAX-102 targeting high-need areas such as autism spectrum disorder and long COVID. Not financial advice.
How frequently does PXMD data refresh on this page?
PXMD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PXMD's recent stock price performance?
PaxMedica, Inc. Common Stock (PXMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline targeting high-need neurological conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PXMD overvalued or undervalued right now?
PaxMedica, Inc. Common Stock (PXMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PXMD before investing?
Before investing in PaxMedica, Inc. Common Stock (PXMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Company financials are limited due to its OTC classification and early-stage status.